The 85% layoff* implies that OPHT itself does not think the remaining Fovista phase-3 trial (#msg-127189251) is likely to succeed. This is sound reasoning in light of the Fovista and REGN failures for this MoA. Canceling the second year of observation in the failed phase-3 Fovista trials also makes sense.
I suppose management deserves some credit for acknowledging that the company is in dire straits.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.